Patrick O'Shaughnessy hosts Alex Carnell, a leading biotech investor with 20 years of experience building and backing life sciences companies. Alex serves as co-founder of Braidwell, previously co-ran Deerfield Management, and provides deep insights into the current state of medicine and drug discovery.

The conversation explores Alex's concept of the 'health stack' - a comprehensive approach to preventive medicine spanning five key areas: lipid optimization, cardiometabolic health, neurocognitive protection, inflammatory control, and blood pressure management. They examine breakthrough medicines like GLP-1 drugs and PCSK9 inhibitors that could dramatically extend human lifespan if adopted proactively.

Alex shares his perspective on AI's transformative impact on drug discovery, the rise of citizen pharmacology through peptide communities, and the commercial success of medicines like semaglutide that demonstrate consumer demand for proactive health interventions. The discussion concludes with Alex's personal journey from Wall Street derivatives trading to becoming a force for closing the gap between medical invention and real-world health impact.

The GLP-1 Revolution and Proactive Health Adoption

2025 represents the most exciting year in Alex's 20-year biotech career, driven by GLP-1 medicines proving that consumers will vote with their feet for proactive health interventions rather than waiting for reactive disease treatment.

GLP-1 medicines demonstrate unprecedented commercial success, easily exceeding $100 billion annually in revenue, because they address root causes of disease across multiple systems - from diabetes prevention to cardiovascular protection to addiction treatment.

The gap between medical invention and health impact isn't lack of medicines - scientists have already cracked the code on most diseases that will claim our lives, but the medicines aren't being deployed proactively.

Expected lifespan charts haven't budged in decades since the last major advancement from antibiotics, vaccines, and better hygiene, despite having the medicines needed to add an extra decade of life.

The Five-Layer Defensive Health Stack Framework

The health stack consists of five critical defensive layers: lipid optimization (cholesterol management), cardiometabolic health (glucose and visceral fat), neurocognitive health (amyloid plaque prevention), inflammatory health, and blood pressure control.

Most middle-aged adults face 30-50% probability of heart attack or stroke between ages 40-80, but existing medicines can reduce this risk to under 10% through proactive intervention.

LDL cholesterol accumulates slowly in vasculature over time, creating blockages that cause heart attacks and strokes - but we have statins and PCSK9 inhibitors that can dramatically lower these levels.

High glucose levels make vasculature more brittle, and when combined with lipid accumulation and inflammatory environments from poor diet, creates a 'ticking time bomb' for cardiovascular events.

GLP-1 Mechanics and Market Dynamics Breakthrough

GLP-1 is a naturally produced hormone lasting only two minutes in the body - the breakthrough was extending this to week-long or daily dosing, eliminating the need for 30 injections per hour.

When food reaches the small intestine, it triggers GLP-1 release, which slows digestion, increases satiation, and regulates insulin production - turning off 'food noise' and enabling dramatic calorie reduction.

Oral Wegovy launched at $150/month has driven weekly new GLP-1 prescriptions from 200,000 to 300,000 patients, demonstrating massive price elasticity in the market.

Compounded GLP-1s at half the cost of approved versions captured 15-20% market share, proving people will take safety risks for health benefits when price becomes accessible.

Eli Lilly's LilyDirect platform showed that over half of new patients prefer direct-to-consumer access rather than traditional doctor-pharmacy channels, indicating demand for consumer-like healthcare products.

PCSK9 Inhibitors as the Ultimate Free Lunch Drug

PCSK9 medicines were discovered through human genetics - populations with genetic mutations that don't produce PCSK9 protein show 88% reduction in cardiovascular disease risk over 15 years.

PCSK9 protein interferes with the body's ability to clear LDL cholesterol - blocking this protein allows natural cholesterol clearance, reducing bad cholesterol by 50%.

Unlike GLP-1s which have real toxicity (nausea, vomiting, gallstones, pancreatitis), PCSK9 inhibitors represent a true free lunch with minimal side effects and massive cardiovascular protection.

RNA interference versions of PCSK9 inhibitors require only two injections per year versus 26, dramatically improving compliance for this silent killer prevention.

Alex believes everyone should eventually be on PCSK9 inhibitors because cardiovascular disease is a silent killer - you feel nothing until the heart attack or stroke occurs.

Neurodegenerative and Cancer Treatment Frontiers

Anti-amyloid medicines from Biogen and Eli Lilly can break up brain plaques and slow Alzheimer's decline by 30% - the key is starting treatment before significant brain damage occurs.

Early intervention with anti-amyloid drugs could potentially turn off the faucet of new plaque formation, similar to how GLP-1s prevent diabetes progression when started in pre-diabetic patients.

Cancer remains challenging because it's often identified too late and has survival instincts - medicines that initially shrink tumors to zero can become ineffective as resistant cells proliferate.

Multi-cancer early detection blood tests from companies like Exact Sciences and Garden Health are improving, with Garden Health moving from stool-based to simple blood tests for better compliance.

CAR-T cell therapies represent a new modality showing dramatic efficacy - reducing tumors by 100% in 70%+ of patients and maintaining responses for extended periods.

AI-Driven Drug Discovery Revolution

AI is moving drug discovery toward scientific superintelligence, where scientists armed with Einstein-level agentic resources can do science faster, cheaper, and with higher probability of success.

Companies like Lila Sciences and Anabla can now go from model to molecule in one month versus traditional multi-year timelines, using fully automated robotic laboratory systems.

The key breakthrough is generating novel scientific data tokens rather than training on existing literature, which often contains incorrect results that don't replicate.

Future drug discovery will be completely automated with agentic systems driving robots to perform experimentation, freeing human scientists from bench work to focus on strategic problem-solving.

AI companies with access to significant capital and novel data generation capabilities are starting to show deterministic scaling laws toward scientific superintelligence.

Alex Carnell's Journey from Wall Street to Biotech Impact

Alex learned entrepreneurial risk-taking from his father's relentless business pursuits and resilience from his mother's 'we always commit and never quit' philosophy, despite being first in his family to attend college.

Serendipitously assigned to biotech derivatives at Merrill Lynch, Alex discovered the life-and-death risk-reward dynamics of medicine development and fell in love with the field's potential impact.

After developing novel portfolio strategies that initially received zero responses, Jeff Kaplan at Deerfield Management became the one person interested, leading to Alex's 15-year journey building Deerfield into an industry epicenter.

A dark period emerged when Alex discovered that patients weren't staying on life-saving medicines - taking them for only one year on average before quitting, questioning whether the industry was optimizing for returns rather than health impact.

Co-founding Braidwell with Brian Kreider represents Alex's mission to close the gap between medical invention and impact, designing the operating system for human health from first principles.